HKSE - Delayed Quote HKD

Charmacy Pharmaceutical Co., Ltd. (2289.HK)

13.940 -0.040 (-0.29%)
At close: 3:50 PM GMT+8
Loading Chart for 2289.HK
DELL
  • Previous Close 13.980
  • Open 14.300
  • Bid 13.940 x --
  • Ask 14.200 x --
  • Day's Range 13.000 - 14.300
  • 52 Week Range 5.900 - 20.000
  • Volume 133,000
  • Avg. Volume 145,559
  • Market Cap (intraday) 1.506B
  • Beta (5Y Monthly) -0.31
  • PE Ratio (TTM) 27.33
  • EPS (TTM) 0.510
  • Earnings Date Mar 29, 2024
  • Forward Dividend & Yield 0.50 (3.57%)
  • Ex-Dividend Date Jun 29, 2023
  • 1y Target Est --

Charmacy Pharmaceutical Co., Ltd. engages in pharmaceutical distribution business in the People's Republic of China. The company distributes western medicines, Chinese patent medicines, healthcare products, and related consulting services to downstream distributors and retail terminals. It also operates Charmacy e-Medicine, a B2B e-commerce platform to place orders online, make inquiries and payments, etc. The company was formerly known as Chuangmei Pharmaceutical Co., Ltd. and changed its name to Charmacy Pharmaceutical Co., Ltd. in July 2016. Charmacy Pharmaceutical Co., Ltd. was incorporated in 1984 and is headquartered in Shantou, the People's Republic of China.

www.chmyy.com

831

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 2289.HK

Performance Overview: 2289.HK

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

2289.HK
7.56%
HANG SENG INDEX
3.54%

1-Year Return

2289.HK
89.82%
HANG SENG INDEX
10.03%

3-Year Return

2289.HK
216.32%
HANG SENG INDEX
39.30%

5-Year Return

2289.HK
112.95%
HANG SENG INDEX
40.27%

Compare To: 2289.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2289.HK

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    1.51B

  • Enterprise Value

    2.51B

  • Trailing P/E

    27.20

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.32

  • Price/Book (mrq)

    2.34

  • Enterprise Value/Revenue

    0.57

  • Enterprise Value/EBITDA

    23.15

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.17%

  • Return on Assets (ttm)

    2.22%

  • Return on Equity (ttm)

    8.61%

  • Revenue (ttm)

    4.4B

  • Net Income Avi to Common (ttm)

    51.34M

  • Diluted EPS (ttm)

    0.510

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    634.2M

  • Total Debt/Equity (mrq)

    214.37%

  • Levered Free Cash Flow (ttm)

    --

Company Insights: 2289.HK

People Also Watch